BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) and Willis Lease Finance (NASDAQ:WLFC – Get Free Report) are both small-cap industrials companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Risk & Volatility
BioNexus Gene Lab has a beta of 4.28, suggesting that its share price is 328% more volatile than the S&P 500. Comparatively, Willis Lease Finance has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.
Valuation and Earnings
This table compares BioNexus Gene Lab and Willis Lease Finance”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioNexus Gene Lab | $7.43 million | 0.35 | -$2.98 million | ($1.26) | -0.71 |
| Willis Lease Finance | $730.24 million | 1.45 | $113.76 million | $3.37 | 13.79 |
Willis Lease Finance has higher revenue and earnings than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Willis Lease Finance, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BioNexus Gene Lab and Willis Lease Finance’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioNexus Gene Lab | -82.38% | -32.92% | -29.75% |
| Willis Lease Finance | 9.38% | 11.89% | 2.20% |
Analyst Recommendations
This is a summary of current recommendations and price targets for BioNexus Gene Lab and Willis Lease Finance, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioNexus Gene Lab | 1 | 0 | 0 | 0 | 1.00 |
| Willis Lease Finance | 1 | 1 | 1 | 1 | 2.50 |
Willis Lease Finance has a consensus price target of $75.50, indicating a potential upside of 62.47%. Given Willis Lease Finance’s stronger consensus rating and higher probable upside, analysts clearly believe Willis Lease Finance is more favorable than BioNexus Gene Lab.
Institutional & Insider Ownership
18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 93.7% of Willis Lease Finance shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by insiders. Comparatively, 56.4% of Willis Lease Finance shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Willis Lease Finance beats BioNexus Gene Lab on 14 of the 15 factors compared between the two stocks.
About BioNexus Gene Lab
BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology and molecular diagnostics company focused on using genetic and genomic information to support disease screening, risk assessment and personalized healthcare. The company develops and commercializes diagnostic products and laboratory services based on the analysis of biological samples, including blood and other specimens. Its offerings are intended to help identify potential health risks and support the early detection and management of conditions such as cancer and other diseases.
About Willis Lease Finance
Willis Lease Finance Corporation is an aviation services company specializing in the leasing and servicing of commercial aircraft engines. Founded in 1985, the company provides engines and related equipment to airlines, aircraft operators and maintenance providers. Its activities include leasing aircraft engines and auxiliary power units, trading engines and parts, and providing aviation maintenance and repair services. Willis Lease Finance also manages engine and equipment portfolios for customers.
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
